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Abstract
Background: In August 2006 a major epidemic of bluetongue virus serotype 8 (BTV8) started off
in North-West Europe. In the course of 2007 it became evident that BTV8 had survived the winter
in North-West Europe, re-emerged and spread exponentially. Recently, the European Union
decided to start vaccination against BTV8. In order to improve the understanding of the
epidemiological situation, it was necessary to execute a cross-sectional serological study at the end
of the BT vector season. Cattle were the target species for cross-sectional serological studies in
Europe at the end of 2006 and 2007. However, there was no information on the BTV8-
seroprevalence in sheep and goats.
Results: On the basis of our cross-sectional study, the estimated seroprevalence of BTV8-exposed
locations in the Netherlands in 2006 was 0% for goats (95% confidence interval: 0 – 5.6%) and 7.0%
for sheep (95% confidence interval: 3.5 – 12.9%). The estimated seroprevalence of BTV-8 exposed
locations in 2007 was 47% for goats (95% confidence interval: 36 – 58%) and 70% for sheep (95%
confidence interval: 63 – 76%). There was a wide range in within-location seroprevalence in
locations with goats and sheep (1 – 100%). A gradient in seroprevalence was seen, with the highest
level of seroprevalence in the southern Netherlands, the area where the epidemic started in 2006,
and a decreasing seroprevalence when going in a northern direction.
Conclusion: There is a much higher estimated seroprevalence of locations with goats exposed to
BTV8 than can be inferred from the rather low number of reported clinical outbreaks in goats. This
is probably due to the fact that clinical signs in infected goats are far less obvious than in sheep. The
wide range in within-location seroprevalence observed means that the proportion of animals
protected in 2008 by a natural infection in 2006 and/or 2007 can differ highly between flocks. This
should be taken into account when vaccinating animals.
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In August 2006 a major epidemic of bluetongue virus
serotype 8 (BTV8) started off in North-West Europe,
including the Netherlands, Belgium, Germany, Luxem-
bourg and the North of France [1,2]. In order to improve
the understanding of the epidemiological situation of this
disease, it was necessary to execute a cross-sectional sero-
logical study at the end of the vector season of 2006. The
Community legal framework on bluetongue monitoring
and surveillance was laid down in Council Directive
2000/75/EC and Commission Decision 2005/393/EC
and these are in line with the Terrestrial Animal Health
Code of the OIE. Cattle were the target species for the
cross-sectional serological study at the end of 2006 [3,4].
Many hoped that the winter season of 2006/2007 would
halt the BTV epidemic, assuming that the chain of trans-
mission would be broken by the dying off of infected
adult vectors and a halt in the life cycle of the vector
because of low temperatures. However, in the course of
2007 it became evident that BTV8 somehow had survived
the winter in North-West Europe and a re-emerging epi-
demic spread exponentially within the original affected
countries. Moreover, BTV8 was introduced into the
United Kingdom, Denmark, Czech Republic and Switzer-
land [5].
The scale of the epidemic in 2007 was so huge that the
European Union decided to start vaccination against BTV8
in 2008. The vaccination campaign aims to achieve a 80%
or more coverage of animals protected (either by vaccina-
tion or by immunity acquired through natural infection)
[6].
The sentinel monitoring system, set up at the beginning of
2007 to detect re-emergence of BTV8, already provided
some insights into the extend of the BTV8 spread in the
cattle population in 2007. However, with respect to goats
and sheep there was no information on the BTV8-sero-
prevalence in North-West Europe. This paper presents the
seroprevalence and geographical spread of BTV8 on ani-
mal and herd levels in goats and sheep in the Netherlands
in 2006 and 2007.
Methods
Blood samples from Dutch sheep and goats were serolog-
ically tested at the Central Veterinary Institute (CVI) in
Lelystad for antibodies against BTV8 using a competitive
ELISA (Institute Pourquier, Montpellier, France). This
ELISA has a high sensitivity (~100%) and specificity
(>99.8%) [7]. The blood samples were collected in the
framework of obligatory and voluntary health pro-
grammes (e.g. certified disease-free programmes within
the European Union) executed by the Dutch Animal
Health Service. For the 2006 seroprevalence estimates, we
used blood samples collected in the first months of 2007.
For the 2007 seroprevalence estimates, we used blood
samples collected in the last months of 2007. Locations
with animal sampled were selected proportional to the
population distribution of locations with goats and sheep
in the Netherlands in the different provinces. Sample size
within locations for the health programmes was set at
detecting at least a prevalence of disease of 5%. In smaller
flocks this often meant that almost all animals within the
flock were sampled.
There are approximately 41,000 locations with sheep and
23,000 locations with goats in the Netherlands registered
at the Animal Health Service. Based on these data and an
a priori estimated seroprevalence of BTV8-infected loca-
tions with goats of 5% and a maximum acceptable error
in the estimated prevalence of 5% and a 95% confidence
level required for the estimated prevalence, a sample size
of approximately 70 locations with goats was calculated
using WinEpiscope version 2.0 [7] for our cross-sectional
study in 2006. For 2007, we adjusted the a priori esti-
mated seroprevalence of BTV-8 infected locations with
goats to 30% with a maximum acceptable error in the esti-
mated prevalence of 10% and a 95% confidence level
required for the estimated prevalence, resulting in a sam-
ple size of approximately 81 locations with goats for
2007. For the locations with sheep, we used an a priori
estimated prevalence of BTV8-infected locations with
sheep of 10% and a maximum acceptable error in the esti-
mated prevalence of 5%, resulting in a calculated sample
size of approximately 140 locations with sheep for 2006.
For 2007, we adjusted the a priori estimated seropreva-
lence to 50% with a maximum acceptable error in the esti-
mated prevalence of 7.5% and a 95% confidence level
required for the estimated prevalence, resulting in a sam-
ple size of approximately 170 locations. Since there is also
an unknown number (not registered) of small-holder
locations in the Netherlands with goats and sheep with a
small numbers of animals (1 to 5 animals per location),
we arbitrarily increased the actual sample size with
approximately 15 to 20%. Exact confidence intervals for
the estimated seroprevalence were calculated according to
Fleiss [9].
Results
Seroprevalence of BTV8-infected locations with goats and 
sheep in 2006
A total of 1,975 goat sera from 83 locations with goats and
2,555 sheep sera from 143 locations with sheep were col-
lected. All goat samples were seronegative, a total of 17
sheep samples (0.7%) from 10 locations with sheep
(7.0%) were seropositive. The BTV8-seropositve locations
with sheep were located in the provinces of Limburg,
North Brabant, Zeeland, and Gelderland. Within-location
seroprevalence ranged from 3 to 50% (almost all sheepPage 2 of 5
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provinces in the Netherlands is shown in Figure 1. Based
on our sampled population we estimated the proportion
of BTV8-seropositive locations in the Netherlands with
sheep and goats. On a national level the estimated sero-
prevalence of BTV8-exposed locations in 2006 was 0% for
goats (95% confidence interval: 0 – 5.6%) and 7.0% for
sheep (95% confidence interval: 3.5 – 12.9%).
Seroprevalence of BTV8-infected locations with goats and 
sheep in 2007
A total of 1,995 goat sera from 81 locations with goats and
4,252 sheep sera from 214 locations with sheep were col-
lected. A total of 204 goat samples (10.2%) from 38 loca-
tions with goats (46.9%) were seropositive. The BTV8-
seropositve locations with goats in 2007 were located in
the provinces of North Holland, South Holland, Utrecht,
Gelderland, North Brabant, and Limburg.
A total of 1,627 sheep samples (38.3%) from 149 loca-
tions with sheep (69.6%) were seropositive. The BTV8-
seropositve locations with sheep were located in all prov-
inces of the Netherlands in 2007. On a national level the
estimated seroprevalence of BTV8-exposed locations in
2007 was 47% for goats (95% confidence interval: 36 –
58%) and 70% for sheep (95% confidence interval: 63 –
76%). The median within-location seroprevalence on
BTV8-infected locations with goats was 21% (min – max:
1 – 100%) and with sheep 67% (min – max: 1 – 100%)
(Figure 2).
Discussion
There is very sparse information on seroprevalence of
BTV-infected locations with goats and sheep during out-
breaks. A cross-sectional study in Kazakhstan showed a
within-herd seroprevalence in cattle, sheep and goats var-
ying between 0 and 100% [10]. A cross-sectional study in
sheep flocks in Northern Pakistan [11] indicated 90% of
the flocks seropositive. In these seropositive sheep flocks,
within-flock seroprevalence ranged from 12 to 100%
(median: 47%). A cross-sectional serological study in
Queensland, Australia, found within-flock seropreva-
lences in infected sheep flocks ranging from 1 – 42% and
in infected goat flocks ranging from 5 – 16% [12].
During the 2006-epidemic in North-West Europe, no clin-
ically affected goats were reported [3]. The results of our
seroprevalence study is in line with those findings. How-
ever, in week 35 of 2007, the first clinical disease in goats
caused by BTV8 in North-West Europe was reported from
the Netherlands [13]: in a holding containing 600 milk-
ing goats, 10 goats demonstrated clinical signs of BT, start-
ing with acute drop in milk yield and pyrexia, followed by
edema of lips and face, crusts on lips and muzzle, nasal
discharge, conjunctivitis and erythema of the udder. Up to
the end of 2007, a total of 25 holdings reported clinical
disease (BT indicative) in goats in the Netherlands. The
results of our seroprevalence study indicate a seropreva-
lence of locations with goats of approximately 50% in the
Netherlands in 2007. This is much higher than can be
inferred from the 25 locations that reported clinical out-
breaks in goats in 2007. This is probably due to the fact
that clinical signs in infected goats are far less obvious
than in sheep [14].
In the first year (2006) of the BTV8-epidemic in the Neth-
erlands, a total of 270 sheep flocks and 200 cattle herds
reported clinical disease. In 2007, the epidemic really
took off: about 3,200 clinical outbreaks were reported by
locations with sheep on a total of 6,500 outbreaks
reported. The results of the seroprevalence study in sheep
in 2006 and 2007 are in line with the number of clinical
outbreaks reported.
In our study we see a wide range in within-location sero-
prevalence in locations with goats and sheep. This means
that the proportion of animals protected in 2008 by a nat-
Geographical location of the twelve provinces in the Nether-lands (DR: Drente; FL: Flevoland; FR: Friesland; GL: Gelder-; GR: Groningen; L: Limburg; NB: North Brabant; NH: North Holl nd; OV: Overijssel; UT: Ut cht; ZH: South olZL: Zeela d)Figure 1
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between locations. Two options for a vaccination strategy
are open: either one vaccinates all ruminants on the loca-
tions with animals irrespective of the proportion of ani-
mals protected by a natural infection in 2006 or 2007 or
one determines the proportion of animals protected by a
natural infection within the flock: if a low to moderate
proportion of animals is naturally protected one has a
good reason to vaccinate all the animals; if a high propor-
tion of animals is naturally protected, this might be a rea-
son not to vaccinate the flock.
Conclusion
Seroprevalence of BTV8-exposed locations with goats and
locations with sheep was much higher in 2007 than in
2006. There was a much higher estimated seroprevalence
of locations with goats exposed to BTV8 than can be
inferred from the rather low number of reported clinical
outbreaks in goats. This is probably due to the fact that
clinical signs in infected goats are far less obvious than in
sheep. There was a wide range in within-location sero-
prevalence in locations with goats and sheep. This means
that the proportion of animals protected in 2008 by a nat-
ural infection in 2006 and/or 2007 can differ highly
between flocks. This should be taken into account when
vaccinating animals.
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